Last reviewed · How we verify
Intravitreal bevacizumab and dexamethasone implant Injection
Intravitreal bevacizumab and dexamethasone implant Injection is a Small molecule drug developed by Yeungnam University College of Medicine. It is currently FDA-approved. Also known as: Intravitreal dexamethasone implant.
At a glance
| Generic name | Intravitreal bevacizumab and dexamethasone implant Injection |
|---|---|
| Also known as | Intravitreal dexamethasone implant |
| Sponsor | Yeungnam University College of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery (NA)
- Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO (PHASE4)
- Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma (PHASE2)
- Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO (PHASE4)
- Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema (PHASE4)
- Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) (NA)
- Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema
- Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal bevacizumab and dexamethasone implant Injection CI brief — competitive landscape report
- Intravitreal bevacizumab and dexamethasone implant Injection updates RSS · CI watch RSS
- Yeungnam University College of Medicine portfolio CI
Frequently asked questions about Intravitreal bevacizumab and dexamethasone implant Injection
What is Intravitreal bevacizumab and dexamethasone implant Injection?
Intravitreal bevacizumab and dexamethasone implant Injection is a Small molecule drug developed by Yeungnam University College of Medicine.
Who makes Intravitreal bevacizumab and dexamethasone implant Injection?
Intravitreal bevacizumab and dexamethasone implant Injection is developed and marketed by Yeungnam University College of Medicine (see full Yeungnam University College of Medicine pipeline at /company/yeungnam-university-college-of-medicine).
Is Intravitreal bevacizumab and dexamethasone implant Injection also known as anything else?
Intravitreal bevacizumab and dexamethasone implant Injection is also known as Intravitreal dexamethasone implant.
What development phase is Intravitreal bevacizumab and dexamethasone implant Injection in?
Intravitreal bevacizumab and dexamethasone implant Injection is FDA-approved (marketed).
Related
- Manufacturer: Yeungnam University College of Medicine — full pipeline
- Also known as: Intravitreal dexamethasone implant
- Compare: Intravitreal bevacizumab and dexamethasone implant Injection vs similar drugs
- Pricing: Intravitreal bevacizumab and dexamethasone implant Injection cost, discount & access